Ed Addison

Ed Addison co-founded Cloud Pharmaceuticals in 2009. Addison is a serial entrepreneur who founded three previous ventures, two of which successfully merged with public companies. He has a unique and strong blend of in-depth business and technical experience in biotechnology and in information technology. Addison holds an MS in Biomedical Engineering from Johns Hopkins University and MBA from Duke University Fuqua School of Business, including a diploma in Duke’s Health Sector Management Program.

From 2000-2009, Addison focused on a series of ventures in the pharmaceutical and life sciences space. These included start-ups in the life sciences market, including BioFortis, a LIMS venture in Baltimore, and Inclinix, a CRO in Wilmington, NC, and TeraDisc, the predecessor of Cloud Pharmaceuticals, where he was named “Coastal Entrepreneur of the Year” in 2009. Addison has been working in drug discovery and development for over 12 years. As a life sciences business development professional, he has negotiated numerous licenses for therapeutics and technology. He spent the early part of his career in information technology.

Addison has been an adjunct professor for over 25 years. Previously he taught at Johns Hopkins University where he developed courses in bioinformatics and entrepreneurship. He was the co-founder and program director of the online MS degree in Bioinformatics for Johns Hopkins University’s Whiting School. Addison received prior awards for entrepreneurship including “Entrepreneur of the Year” in 1994 by the Information Industry Association and #51 on the National Fast 500, and Coastal Entrepreneur of the Year in 2009. He is the author of a book called Leveraging the Horizon about seed-stage technology ventures.

Speaker Details
Events of the Speaker
You might also love these events.
Meridian Clinical Trials - Presentation
November 22, 2021
5th Meridian Clinical Trials is a nexus of the clinical trials industry for networking, knowledge sharing, collaboration, and partner outreach. MCT partners with leading research institutions, private pharma-biotechs, and contract research organizations to stay updated about the latest scientific knowledge, research, and technology.
Upcoming